Warning: The NCBI web site requires JavaScript to function. more...
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration.
Hurley SF, Matthews JP, Guymer RH.
Cost Eff Resour Alloc. 2008 Jun 24;6:12.
Related citations
Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.
Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76. Epub 2009 Aug 11.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.
Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
Clin Ther. 2008 Dec;30(12):2436-51.
A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM, Brown GC, Brown HC, Peet J.
Ophthalmology. 2008 Jun;115(6):1039-1045.e5. Epub 2007 Nov 5.
Cost-effectiveness of smoking cessation to prevent age-related macular degeneration.
Cost Eff Resour Alloc. 2008 Sep 11;6:18.
Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP.
J Eval Clin Pract. 2010 Sep 16. doi: 10.1111/j.1365-2753.2010.01546.x. [Epub ahead of print]
Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC, Lade RJ, Adewoyin T, Chong NV.
Ophthalmology. 2008 Dec;115(12):2192-8. Epub 2008 Oct 18.
[Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.
Klin Monbl Augenheilkd. 2007 Sep;224(9):727-32. German.
The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, Saaddine JB.
Ophthalmology. 2009 May;116(5):823-32. Epub 2009 Mar 14.
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP.
J Manag Care Pharm. 2010 Apr;16(3):217-30. Review.
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.
Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.
Pharmacoeconomics. 2007;25(10):863-79.
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.
Smith DH, Fenn P, Drummond M.
Br J Ophthalmol. 2004 Sep;88(9):1107-12.
Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece.
Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J.
Clin Ther. 2012 Jan 28. [Epub ahead of print]
The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Sharma S, Brown GC, Brown MM, Hollands H, Shah GK.
Ophthalmology. 2001 Nov;108(11):2051-9.
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
Health Technol Assess. 2005 Jun;9(22):1-160. Review.
The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.
Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.
Trans Am Ophthalmol Soc. 2007;105:160-9; discussion 169-71.
[Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].
Yanagi Y, Aihara Y, Fukuda T, Hashimoto H.
Nihon Ganka Gakkai Zasshi. 2011 Sep;115(9):825-31. Japanese.
Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
Earnshaw SR, Moride Y, Rochon S.
Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on